Biomarkers in scleroderma: Current status

L. Gupta, S. Phatak, S. Edavalath

Research output: Contribution to journalArticlepeer-review

Abstract

Scleroderma is an autoimmune disease characterized by indolent obliterative vasculopathy and widespread fibrosis. The two main morphological manifestations of the disease overlap and may make it difficult to separate activity from damage. Many patients, especially those with the limited subset of the disease, have an indolent course without clear-cut inflammatory manifestations. There is a felt need for validated biomarkers, which can differentiate activity from damage, and yet be sensitive to change with therapy. Multiplex arrays of biomarkers have ushered an era of targeted or personalized medicine based on phenotypic characteristics in an individual.
Original languageEnglish
Pages (from-to)S149-S155
Number of pages7
JournalIndian Journal of Rheumatology
Volume12
Issue number6
Publication statusPublished - 1 Nov 2017

Keywords

  • Biomarkers
  • Fibrosis
  • Systemic sclerosis

Fingerprint

Dive into the research topics of 'Biomarkers in scleroderma: Current status'. Together they form a unique fingerprint.

Cite this